The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
Fair W, Cookson M, Stroumbakis N, Cohen D, Aprikian A, Wang Y, Russo P, Soloway S, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg C, Heston W, Reuter V. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997, 49: 46-55. PMID: 9123736, DOI: 10.1016/s0090-4295(97)00169-6.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyMargin-positive rateADT groupPathologic stagingRadical prostatectomyProstatic cancerMonths of ADTControl groupNeoadjuvant androgen deprivation therapyPreoperative androgen deprivation therapyDisease-free survival ratesDisease-free rateMonths of goserelinNeoadjuvant androgen deprivationPSA failure ratesPhase II studySubset of patientsAdditional therapeutic interventionsArea of oncologyDefinitive surgeryDeprivation therapyNeoadjuvant chemotherapyPSA failureBiochemical failureControl patients